BACKGROUND Adverse drug reactions (ADRs) increase health-care resource utilization, including that for emergency department (ED) visits. However, cost analyses of ADRs resulting in ED visits are scarce. Therefore, we aimed to estimate the direct medical costs before and after ADR occurrence and analyzed the cost-driving factors. METHODS The ADR cases were identified by a retrospective review of medical records of patients who visited the ED of three tertiary hospitals in South Korea from July to December 2014. The direct medical cost was estimated by the difference in costs six months before and after the ED visit. A generalized linear model was used to identify the ADR-associated cost-driving factors. RESULTS The mean cost per ADR increased by 26.1% (±SD = 4.3) during the six-month follow-up compared with that during the six months before the ED visit (p < 0.05). Preventable ADRs accounted for approximately 19.9% of the cost increase among all ADR cases. The regression analysis revealed that 'ADR-related hospitalization' was a significant (p < 0.05) factor leading to an increase in the direct medical costs. CONCLUSION Drug-related ED visits increase the burden on health insurance systems and patients' out-of-pocket costs, mostly due to the hospitalization costs.

中文翻译：

---

与药品不良事件相关的急诊科就诊的成本影响-韩国的一项多中心研究。

背景技术药物不良反应（ADR）会增加医疗资源的利用率，包括急诊就诊的资源利用率。但是，对导致急诊就诊的ADR进行成本分析的情况很少。因此，我们旨在估算ADR发生前后的直接医疗费用，并分析成本驱动因素。方法通过回顾性回顾韩国2014年7月至2014年12月在三所三级医院就诊的急诊科患者的病历，确定ADR病例。直接医疗费用由急诊前后六个月的费用差异估算得出访问。使用广义线性模型来确定与ADR相关的成本驱动因素。结果每份ADR的平均费用增加了26.1％（±SD = 4。3）在6个月的随访中与ED访视前的6个月相比（p <0.05）。在所有ADR案件中，可预防的ADR约占费用增长的19.9％。回归分析显示，“ ADR相关住院”是导致直接医疗费用增加的重要因素（p <0.05）。结论与药物有关的急诊就诊增加了健康保险系统和患者自付费用的负担，这主要是由于住院费用所致。